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BACKGROUND: Herein, we describe the consensus guideline methodology, summarize the evidence-based recommendations we pro-
vided to the World Health Organization (WHO) for their consideration in the development of global guidance and present a narrative
review of the diagnosis of male infertility as related to the eight prioritized (problem or population (P), intervention (I), comparison (C)
and outcome(s) (O) (PICO)) questions. Additionally, we discuss the challenges and research gaps identiﬁed during the synthesis of this
evidence.
OBJECTIVE AND RATIONALE: The aim of this paper is to present an evidence-based approach for the diagnosis of male infertility as
related to the eight prioritized PICO questions.
SEARCH METHODS: Collating the evidence to support providing recommendations involved a collaborative process as developed by
WHO, namely: identiﬁcation of priority questions and critical outcomes; retrieval of up-to-date evidence and existing guidelines; assess-
ment and synthesis of the evidence; and the formulation of draft recommendations to be used for reaching consensus with a wide range of
global stakeholders. For each draft recommendation the quality of the supporting evidence was then graded and assessed for consideration
during a WHO consensus.
OUTCOMES: Evidence was synthesized and recommendations were drafted to address the diagnosis of male infertility speciﬁcally encom-
passing the following: What is the prevalence of male infertility and what proportion of infertility is attributable to the male? Is it necessary
for all infertile men to undergo a thorough evaluation? What is the clinical (ART/non ART) value of traditional semen parameters? What
key male lifestyle factors impact on fertility (focusing on obesity, heat and tobacco smoking)? Do supplementary oral antioxidants or herbal
therapies signiﬁcantly inﬂuence fertility outcomes for infertile men? What are the evidence-based criteria for genetic screening of infertile
men? How does a history of neoplasia and related treatments in the male impact on (his and his partner’s) reproductive health and fertility
options? And lastly, what is the impact of varicocele on male fertility and does correction of varicocele improve semen parameters and/or
fertility?
WIDER IMPLICATIONS: This evidence synthesis analysis has been conducted in a manner to be considered for global applicability for
the diagnosis of male infertility.
Key words: male infertility / spermatozoa / genetics / Y deletions / cystic ﬁbrosis transmembrane conductance regulator / semen ana-
lysis / varicocele / evidence-based guideline / cancer
Introduction
In 2012, the World Health Organization (WHO) held a meeting of
experts to scope the ﬁeld of fertility care in order to develop com-
prehensive guidelines on infertility. Six Evidence Synthesis Groups
(ESG) were established. One group was the WHO ESG on Male
Infertility: Diagnosis. Following the initial meeting, key PICO (problem
or population (P), intervention (I), comparison (C) and outcome(s)
(O)) questions were developed and agreed upon. This included
working through the WHO GDG (Guideline Development Group)
Committee, as well as through web-based surveys, and through out-
reach to developing country scholars taking an on-line Geneva
Foundation for Medical Education and Research- American Society
for Reproductive Medicine- (GFMER-ASRM) WHO evidence-based
infertility course. For each PICO question, a systematic analysis of the
literature was performed according to the ‘WHO handbook for
guideline development’ (WHO, 2014). A preliminary analysis of the
data was presented to the WHO/GDG Steering Committee
Working Experts Consultation in December 2014 during which mod-
iﬁcations were made to various components of a few of the PICO
questions, and additional PICOs were also identiﬁed. A comprehen-
sive document including draft recommendations was presented to
the WHO/GDG Steering Committee Meeting for Guidelines and
Nomenclatures in September 2015 (Fig. 1). This manuscript provides
a narrative review of the evidence synthesized by the ESG that helped
to generate the recommendations (Table I), provides an update of
the evidence as recommended through expert review, deﬁnes some
of the challenges in addressing these questions and discusses current
research gaps. It concludes by presenting future research opportun-
ities and outlines how these may be realized.
Methods
The key PICO questions
The following eight topics were pre-determined and identiﬁed by WHO,
and were later formulated into PICO questions for systematic analysis, as
follows:
- What is the prevalence of male infertility and what proportion of infer-
tility in the couple is attributable to the male?
- Is it necessary for all infertile men to undergo a thorough evaluation?
- What is the clinical (ART/non ART) value of traditional semen
parameters?
- What key male lifestyle factors impact on fertility (focusing on obesity,
heat and tobacco smoking)?
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- Do supplementary oral antioxidants or herbal therapies signiﬁcantly
inﬂuence fertility outcomes for infertile men?
- What are the evidence-based criteria for genetic screening of infertile
men?
- How does a history of neoplasia and related treatments in the male
impact on (his and his partner’s) reproductive health and fertility options?
- What is the impact of varicocele on male fertility and does correction
of varicocele improve semen parameters and/or fertility?
Outline evidence synthesis methodology
The methodology used to support the provision of the recommendations
was outlined by the WHO (2014) namely: identiﬁcation of priority ques-
tions and critical outcomes; retrieval of up-to-date evidence and existing
guidelines; assessment and synthesis of the evidence; and formulation of
draft recommendations to be used for reaching a consensus with a wide
range of global stakeholders. For each recommendation the quality of the
supporting evidence would then be graded (very low, low, moderate and
high) for consideration for the consensus. For example, a rating of high
quality of evidence means that further research is very unlikely to change
our conﬁdence in the estimate of the effect. Conversely a rating of very
low quality of evidence means that any effect is very uncertain.
We qualiﬁed the strength of our recommendations (as strong or
weak) based upon consideration of the quality of the evidence. These
recommendations were then later assessed through the WHO guideline
development processes that are based upon other factors including
values and preferences of stakeholders, the magnitude of effect, the bal-
ance of beneﬁts versus harm, resource used and the feasibility of
implementation.
Overall, wherever possible, original literature, and data from recently
published systematic and Cochrane reviews were used. However, due to
the diagnostic nature of the questions, a signiﬁcant amount of the litera-
ture addressing them does not lend itself to high evidence level RCTs.
Therefore, in addition, key guidelines and professional committee opi-
nions were examined, in order to assist in developing a broader and
more comprehensive evidence base, as well as in the construction of
recommendations, and in particular: ASRM—Diagnostic evaluation of the
infertile male: a committee opinion (2015) (ASRM, 2015a); American
Urological Association [AUA] Best Practice Statements (updated 2010
and 2011); EAU Guidelines on Male Infertility (Jungwirth et al., 2015); and
the Society for Male Reproduction and Urology (2014) Report on varico-
cele and infertility.
Data were presented in summary form and descriptively, in tables or
narratively in the evidence reviews for each PICO question. Where
appropriate, meta-analyses were conducted. The GRADE framework
was applied to the body of evidence for each outcome within each
PICO. The WHO then used the worksheets to summarize the volume
and quality of the evidence supporting the recommendations as well as
to outline the values, preferences and judgements made about the
strength of recommendations. The uniqueness of the WHO process was
that these balanced worksheets were also to be used to note considera-
tions especially for low- and middle-income countries or settings, and to
be able to record the reasons for changes made to the default strength
of the recommendations.
The principles or best practice guidance need to be consensus-based
and are also intended to underscore the importance of respect for repro-
ductive rights and dignity as recipients of care, and the need to maintain
high ethical and safety standards in clinical practice. These principles, in
addition to the strategies for implementation, monitoring and evaluation,
are expected to guide end-users in the process of adapting and imple-
menting any recommendation provided by the WHO to consider for a
range of global contexts and settings.
WHO Expert meeng to begin to scope comprehensive guidelines for inferlity [28 areas, January 2012]
Priorisaon and idenﬁcaon of 6 Evidence Synthesis Groups (Formaon of ESG Male Diagnosis, 2012-2013)  
Idenfy key PICOs including web based surveys and global outreach for feedback and priorisaon (2013-2014).  
First methodological and systemac analysis of literature to address PICOs according to WHO handbook for guideline development (2014) 
Preliminary analyses presented by Group leads and methodologists to WHO Steering Commiee   [December 2014] 
Presentaon  of detailed analysis and provision of dra recommendaons to Guidelines Development Group [September 2015]  
WHO Assessment of Recommendaons, revision through Guideline Development Process
with mulple stakeholders and independent expert review  (late 2015-2016)  
WHO Comprehensive Guidelines following Guideline Review Commiee assessment
for all 6 priorised areas for inferlity (ancipated, 2017/8)
Figure 1 Outline ﬂowchart of WHO methodology for ESG Male Diagnosis. Flowchart outlining the WHO process for obtaining the evidence,
and formulating and presenting recommendations for male infertility (Diagnosis). This includes stages and methods for synthesis of evidence accord-
ing to WHO process. Dates in square bracket reﬂect speciﬁc meetings at WHO in Geneva. PICO: problem or population (P), intervention (I), com-
parison (C) and outcome(s) (O). WHO, World Health Organization; ESG, Evidence Synthesis Group.
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Table I Male Factor Infertility Diagnosis: Summary Recommendations.
Clinical questions RECOMMENDATIONS through assessment of developed
PICO question and associated evidence analysis
Strength of
the
evidence
1. What is the prevalence of male infertility and what proportion
of infertility is attributable to the male?
It is not possible to determine an unbiased prevalence of male infertility
in the general population.
Very low
2. Is it necessary for all infertile men to undergo a thorough
evaluation?
The initial evaluation for male factor infertility should include a PE
performed by an examiner with appropriate training and expertise, a
reproductive history and at least one properly performed (high quality)
semen analyses. A full evaluation by a urologist or other specialist in male
reproduction should be done if the initial screening evaluation
demonstrates an abnormal PE, an abnormal male reproductive or sexual
history, or an abnormal semen analysis is found. Further evaluation of the
male partner should also be considered in couples with unexplained
infertility and in couples in whom there is a treated female factor and
persistent infertility
Moderate
3. What is the clinical (ART/non ART) value of traditional
semen parameters?
Assessment of a combination of several ejaculate parameters is a better
predictor of fertility success than a single parameter
High
Analysis of a single ejaculate is sufﬁcient to determine the most
appropriate investigation and treatment pathway although semen analysis
could be repeated if one or more abnormalities is found
High
4. What key male lifestyle factors impact on fertility? Evidence supports a detrimental effect of obesity on many aspects of
health; evidence is conﬂicting about a potential effect on reproductive
function. Males presenting for fertility evaluation should be counseled
about weight-loss strategies when the BMI and waist circumference data
demonstrate obesity and especially morbid obesity.
Moderate
There is insufﬁcient evidence to conclude that exposure to heat, be it
occupational or as a result of clothing or body position, affect semen
quality and/or male fertility
Very low
There is some evidence to suggest a negative effect of cigarette
(tobacco) smoking on semen quality but not all studies report this.
However, as smoking has an adverse effect on general health and
wellbeing it is recommended that men trying for a pregnancy should
abstain from smoking
Moderate
5. Do supplementary oral antioxidants or herbal therapies
signiﬁcantly inﬂuence fertility outcomes for infertile men?
There are insufﬁcient data to recommend the use of supplemental
antioxidant therapies for the treatment of men with abnormal semen
parameters and/or male infertility
Low
There are insufﬁcient data to recommend the use of herbal therapies for
the treatment of men with abnormal semen parameters and/or male
infertility
Very low
6. What are the evidence-based criteria for genetic screening of
infertile men?
Karyotype testing should be performed on all males with severe
oligozoospermia (<5×106/ml) or NOA prior to any therapeutic
procedure
High
YCMD testing should be performed on all males with severe
oligozoospermia prior to a therapeutic procedure or NOA prior to any
therapeutic procedure
High
Appropriate CFTR mutation analysis should be offered to all males with
CBAVD or CF
High
7. How does a history of neoplasia and related treatments in the
male impact (his and his partner’s) reproductive health and
fertility options?
Every male cancer patient should be provided with information about the
impact of his cancer treatment on spermatogenesis and the option of
sperm banking
Moderate
Patients should be advised to use contraception if they do not wish to
procreate even after prolonged periods of azoospermia following
radiotherapy, as recovery is possible
Low
Male cancer patients should be informed that pregnancy outcomes in
partners of male cancer survivors are good but a slightly higher risk of
congenital anomalies in their offspring cannot be excluded
Low
Continued
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The evidence based and detailed analysis, with GRADE tables where
possible for each of the prioritized PICO questions, were commissioned
by and provided by the ﬁrst author to the WHO in support of their guide-
line processes. A WHO assessment of our evidence-based outcomes was
then undertaken with many stakeholders who evaluate other factors
including values and preferences of stakeholders, the magnitude of effect,
and the balance of beneﬁts versus harms, resource use and the feasibility
of implementation to better assure global applicability. As required by
WHO, following these outcomes, additional independent expert review
would be conducted (2016 and early 2017). Once completed, the WHO
will be publishing their expert and stakeholder consensus-driven guidelines
together with the detailed evidence base (evidence tables, detailed search
strategies, balanced worksheets etc.) and related products (Fig. 1).
The present manuscript provides a narrative of the evidence. It particu-
larly focuses on areas where evidence is controversial, of poorer quality
and more challenging to obtain. It discusses what is missing from the ana-
lysis and critically provides a discussion of potential research gaps. It is not
the purpose of this manuscript to reproduce the original documents sub-
mitted to the WHO. As it was necessary to undergo a global prioritization
method to identify answerable PICO questions, there inevitably are a
number of questions in the diagnosis of male infertility not addressed by
the WHO ESG and thus absent from this manuscript. For example, the
effect of paternal age, alcohol and environment on male fertility (those
interested can consult for example: Age—Eisenberg & Meldrum, 2017;
Nybo-Andersen and Urjoj, 2017; Johnson et al., 2015; Ramasamy et al.,
2015; Alcohol—Karmon et al., 2017; Jensen et al., 2014; Oil and natural
gas extraction—Balise et al., 2016; Bisphenol A—Mínguez-Alarcón et al.
2016; Outdoor air pollution—Lafuente et al., 2016).
Summary of outcomes and
narrative review as related to
the eight prioritized PICO
questions
The speciﬁc recommendations formulated for the presentation to the
WHO on the diagnosis of male infertility are included in the text
along with an assessment of the quality of the supporting evidence
(Table I) and strengths of recommendations based upon our
evidence synthesis. The ﬁnal recommendations will only result follow-
ing an independent expert review of our work and review by stake-
holder societies, following assessment through the Guidelines Review
Committee of WHO.
What is the prevalence of male infertility
and what proportion of infertility is
attributable to the male?
This is a simple and fundamental question. It is critical to know the
prevalence of a disease in order to provide resources, estimate
impact, make effective health economic arguments, present rational
research questions and manage patients. Investigators studying other
diseases often have the incidence of the disease well established in a
variety of different populations. However, for male infertility this
remarkably simple question is surprisingly very difﬁcult to answer.
The most recent publication presents a population prevalence esti-
mate of infertility amongst 15 162 men and women in the UK (Datta
et al., 2016). This was a cross-sectional survey asking if the partici-
pants had ever had a time, lasting 12 months or longer, when they
and their partner were trying for a pregnancy but it did not happen.
One in eight women (12.5%, 95% CI 11.7–13.1) and one in ten men
(10.1%, 95% CI 9.2–11.1) answered yes to this question and thus
had experience of infertility. This type of study needs repeating in a
number of different geographical regions.
Addressing the prevalence of male infertility is a challenging one.
For example, a difﬁculty arises from a lack of continuity in the deﬁni-
tions of infertility. Generally, infertility is deﬁned as failure of a ‘cou-
ple’ to become pregnant despite 12 or more months of unprotected
intercourse. However, some studies such as Hull et al. (1985) include
in their deﬁnition couples who become pregnant but miscarry. Other
studies such as Anderson et al. (2009) and Gurunath et al. (2011)
include those who seek medical advice in order to be able to make a
partner pregnant. There is no current method to capture men as
individuals or in same-sex relationships, who may desire a biological
child through ART, and who may be found to be infertile.
Furthermore, there is also generally a lack of differentiation between
.............................................................................................................................................................................................
Table I Continued
Clinical questions RECOMMENDATIONS through assessment of developed
PICO question and associated evidence analysis
Strength of
the
evidence
8. What is the impact of varicocele on male fertility and does
correction of varicocele improve semen parameters and/or
fertility?
Good Practice Point: Treatment of a clinically palpable varicocele may be
offered to the male partner of an infertile couple when there is evidence
of abnormal semen parameters and minimal/no identiﬁed female factor,
including consideration of age and ovarian reserve
Very low
Good Practice Point: IVF with or without ICSI may be considered the
primary treatment option when such treatment is required to treat a
female factor, regardless of the presence of varicocele and abnormal
semen parameters
Very low
Good Practice Point: The treating physician’s experience and expertise,
including evaluation of both partners, together with the options available,
should determine the approach to varicocele treatment
Very low
PICO, problem or population (P), intervention (I), comparison (C) and outcome(s) (O); CBAVD, Congenital Bilateral Absence of the Vas Deferens; PE, physical examination;
YCMD, Y chromosome microdeletion; NOA, non-obstructive azoospermia.
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primary and secondary infertility in the heterosexual male, and the rela-
tive rates of primary and secondary infertility vary signiﬁcantly between
studies, especially when comparing clinic-based and population-based
studies (see Malekshah et al., 2011 versus Klemetti et al., 2010).
The varying deﬁnitions used for male infertility and the fact that
men are not always evaluated (Pastuszak et al., 2016) can result in
misleading study conclusions. Mehta et al. (2016) recently documen-
ted many of these obstacles when trying to obtain an accurate assess-
ment of the prevalence of male infertility in the USA. Consequently,
it is not surprising that there are currently no rigorous systematic
reviews or meta-analyses on the epidemiology of male infertility.
Agarwal et al. have attempted to pursue this type of review (Agarwal
et al., 2015) but due to a paucity of high-quality comparable studies
they were unable to make robust conclusions. There are signiﬁcant
variations in the variables assessed between studies, including, but
not limited to the age of the participants, the participants themselves
(individual males, females or couples), the method of data collection
and the outcomes measured. These caveats create inconsistencies in
the study results, and consequently, studies of male infertility can gen-
erally be divided into two categories: those that seek to determine
the prevalence or incidence of the experience of infertility amongst
men, or those which focus on the proportion of total infertility that is
attributable to the male factor. For example, it is insufﬁcient to simply
ask men if they experienced infertility because this information does
not give a true representation of male factor infertility (as their part-
ner could be the cause of the infertility). On the other hand, clinical
studies of diagnosed male factor infertility itself often suffer from small
sample size (Geelhoed et al., 2002) or a biased population—those
that consult—which could skew the data. Not all couples experien-
cing infertility choose to consult a physician and, of couples that do
consult, not all will have experienced greater than 12 months of infer-
tility. For example, Louis et al. (2013) reported a higher prevalence of
infertility than Anderson et al. (2009) using the same study popula-
tion, because the latter’s deﬁnition of infertility was restricted to men
who had gone for a consultation. Similarly, van Roode et al. (2015)
reported a higher prevalence of infertility amongst 38-year-old men
(18.3% compared to 14.4%) when they expanded their deﬁnition of
infertility to include those who had sought medical help to generate a
pregnancy. The selection of subject populations is often inherently
biased. And in the case of assessing male infertility, for example, studies
performed on speciﬁc populations, such as military recruits, may not
reﬂect the general population. Large-scale studies of the prevalence of
infertility generally focus on women’s experience of infertility as
reported in demographic surveys which are based upon contraceptive
usage (e.g. Gurunath et al., 2011, Mascarenhas et al., 2012) and few
large-scale studies are able to gather data on men. Van Roode et al.
(2015) reported a large difference in the diagnosis of fertility problems
when asking women in a survey compared to asking men.
Current studies of male infertility often employ cross-sectional
population study designs (e.g. Datta et al., 2016 above), or are obser-
vational studies of those men who present to infertility clinics. Only
one prospective birth cohort study was identiﬁed (van Roode et al.,
2015). A further limitation of the available literature is that some
studies are relatively old, such as Hull et al. (1985) and Thonneau
et al. (1991); studies which have not been updated in a quarter of a
century. There may also be a geographical variation in the incidence
of male infertility—one study in France suggested that male factor
alone accounted for 20% of total infertility (Thonneau et al., 1991)
whilst a study in Western Siberia put the ﬁgure at 6.4% (Philippov
et al., 1998). It is unclear whether these represent true geographical
variations or simply differences in methodology.
Sufﬁce it to say that, based on current evidence, few reliable con-
clusions can be drawn about the epidemiology of male infertility.
Several studies have suggested that male factor infertility is the single
most common diagnosis among heterosexual couples who struggle
to become pregnant but deﬁnitions and diagnosis of male factor vary
and several other studies report that female factor infertility is more
prevalent. Nevertheless, all of these studies highlight the need for fur-
ther research.
One simplistic and frequently used approach to assess male infertil-
ity has been to examine semen parameters in men of the general
population and determine the frequency of semen abnormalities
against standard ranges (Cooper et al., 2010, Virtanen et al., 2017). A
plethora of studies have done this and also used this information in
an attempt to address changes in semen quality over time (Virtanen
et al., 2017). The advantage of these studies is that they can provide
comparable data but only if ﬁrst the populations are well character-
ized and second the laboratory methods used to determine semen
quality are robust and consistent across study sites (cf. Björndahl
et al., 2016). However, the primary disadvantage of this approach is
that semen parameters alone are not equivalent to deﬁning infertil-
ity/fertility (MacLeod, 1950; Guzick et al., 2001; Cooper et al.,
2010). As such, the focus of the current analysis was on the propor-
tion of heterosexual men who experience a delay (extended time) in
inducing a pregnancy (Fig. 2).
In summary, we strongly recommend, owing to the very low qual-
ity of evidence, that it is not currently possible to determine an
unbiased prevalence of male infertility within the global, regional or
national populations, including neglected individual populations.
Additionally, it is not currently possible to determine what proportion
of infertility in heterosexual couples is attributable to the male part-
ner (Table I).
A number of topics were identiﬁed for future research. There is a
need for large population-based studies to determine the prevalence
of male infertility in the general population of males whether in a rela-
tionship or not. Ideally, large population-based cohort studies con-
ducted in a number of different geographical regions must be carried
out with consistent deﬁnitions of infertility and comparable clinical
study designs.
Is it necessary for all infertile men to
undergo a thorough evaluation?
Medical conditions in the male may be causative of the infertility
(such as hypogonadotropic, hypogonadism or bilateral cryptorchid-
ism) or associated with the infertility (testis tumour in male with nor-
mal semen analysis). The rationale for evaluating the male and the
extent of that evaluation depends on the goals of the evaluation.
Several medical best practice statements (AUA, 2011; ASRM, 2015a)
suggest that the goals of the evaluation of the male are to identify:
conditions that can be corrected; conditions that are irreversible for
which ART will be needed using the male partner’s sperm; irrevers-
ible conditions for which the male partner’s sperm will not be avail-
able or appropriate and may require consideration of donor sperm
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or adoption; serious medical conditions that may be causing or pre-
sent with male infertility and that could affect the health of the male
and require medical treatment; and genetic causes of male infertility
that could affect the success of treatment or the health of offspring if
ART is utilized.
Evaluations of populations of infertile men have identiﬁed patients in
each of these categories emphasizing the need for evaluation of the
male (Nieschlag and Behre, 2001; Tournaye et al., 2016; Olesen et al.,
2017; Punab et al., 2017, Pastuszak et al., 2016). An initial evaluation of
the male consists of three primary components: history, physical examin-
ation (PE) and semen analyses. There is general agreement about the
importance of obtaining a reproductive history (including a sexual his-
tory) and semen analyses. The ASRM (ASRM, 2015a) suggest that the
reproductive history should include: coital frequency and timing; duration
of infertility and previous fertility; childhood illnesses and developmental
history; systemic medical illnesses (such as diabetes mellitus and upper
respiratory diseases); previous surgery; medications and allergies; sexual
history (including sexually transmitted infections); and exposures to
gonadotoxins (including environmental and chemical toxins and heat). A
discussion point, however, is the need, timing of investigations, and indi-
cations for PE; and it is in this area where the current guidance appears
to be inconsistent. Practice statements by the AUA and ASRM recom-
mend an initial evaluation of all males of infertile couples that consists of
a detailed reproductive history and semen analyses. For example, the
ASRM states ‘At a minimum, the initial screening evaluation of the male
partner of an infertile couple should include a reproductive history and
analysis of at least one semen sample’ (ASRM, 2015a). The ASRM then
recommends that those men with risk factors in their reproductive
history or abnormal semen parameters should be referred to a male
reproductive specialist for a more thorough evaluation that includes a
PE. Notably, both organizations (ASRM and AUA) recommend consid-
eration of a full male evaluation (including PE) in those couples with
unexplained infertility or those that remain infertile after correction of
female factors. The European Association of Urology (EAU) states ‘A
medical history and PE are standard assessments in all men’ (Jungwirth
et al., 2015). Others have suggested a full evaluation of all men in infertile
relationships (Honig et al., 1994; Kolettis and Sabanegh, 2001; Olesen
et al., 2017; Punab et al., 2017), which includes a PE.
The question is: Which diagnostic strategy is optimal? A signiﬁcant
number of identiﬁed male factors are associated with abnormalities
found by semen analysis. However, the aetiology remains to be
robustly quantiﬁed, especially in light of causes of infertility such as
birth defects, acquired forms of infertility, infection, inability to have
an erection or ejaculation, various syndromes as well as metabolic
and endocrine disorders. Sexual dysfunction may be associated with
normal semen parameters but can be identiﬁed through a sexual his-
tory. Additionally, there are a number of genetic syndromes that pre-
dispose or cause male infertility some of which are associated with
abnormal semen parameters. An initial evaluation of the male consist-
ing of a reproductive history, a simple PE and semen analysis would
potentially identify the majority of these cases, however, these eva-
luations must also be sensitive to different cultural practices and dif-
ferent regional aetiologies, e.g. HIV, genital tuberculosis (TB) in TB
endemic areas, lifestyle, environmental and occupational hazards.
Signiﬁcant medical conditions have been reported in 1.1–6% of men
presenting for infertility evaluations and a number of these men have
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Figure 2 Prevalence of male infertility. Prevalence of male infertility in surveys of general populations. Male infertility was generally deﬁned as men
reporting experience of infertility (generally >12 months in duration).
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abnormal semen parameters. Importantly, however, there are limited
data on the incidence of signiﬁcant medical conditions that predispose
men to infertility. One older data series reported that 0.16% of men
had signiﬁcant medical conditions but normal semen parameters
indicating that conditions will be missed by limiting a male assessment
to a reproductive history and semen analysis (Honig et al., 1994).
Consequently, there are several approaches that can be utilized con-
sisting of the following possibilities. One approach is that all sub-fertile
men should have an initial evaluation with history, PE by an examiner
with appropriate training and expertise, and a semen analysis.
Importantly, this will pick up conditions missed by excluding a PE and is
consistent with the EAU guidelines (Jungwirth et al., 2015).
Alternatively, initial evaluation consists of detailed reproductive history
and semen analyses; in this scenario, only if either is abnormal does
the male undergo a more thorough history and a PE. However, men
with signiﬁcant medical conditions will be missed by this approach. On
balance, there are, on a global scale, a number of advantages and few
disadvantages to include a PE performed by an examiner with appro-
priate training and expertise as part of this initial evaluation. For
example, in low- to middle-income countries where visits to infertility
health professionals will be more restricted due to factors such as
geography and costs, it is less likely that a man will return to the clinic
even if the results of a semen analysis are abnormal.
Interestingly, both ASRM and EAU ASRM do not recommend endo-
crine testing as a primary ﬁrst line investigation. For example, the ASRM
(2015a) suggest endocrine testing in men with abnormal semen para-
meters (particularly when the sperm concentration I < 10million/ml),
impaired sexual function or clinical ﬁndings that suggest a speciﬁc endo-
crinopathy. And, as ASRM state, some experts think that all infertile
men merit an endocrine evaluation (Ventimiglia et al., 2016; Olesen
et al., 2017). What is important is that the key recommendations are
veriﬁed in different populations to establish how robust they are, and if
required such recommendations are amended. Interestingly, Ventimiglia
et al. have recently examined the ASRM indications for endocrine
assessments in a cross-sectional study of 1056 infertile men to predict
hypogonadism. Using the same database, the authors developed a logis-
tic regression-based nomogram including testis volume measured during
the physical exam, BMI and azoospermia to predict total testosterone
levels of <3 ng/dl. Although, their nomogram had a higher predictive
accuracy (68%) than ASRM’s guidelines (58%), they concluded, based
on their statistical analyses, that their nomogram also was not reliable
enough to predict hypogonadism. These examples emphasize the
importance of validating recommendations in a variety of populations.
In summary, we strongly recommend based on a moderate quality
of evidence that:
- The initial evaluation for male factor infertility should include a PE
performed by an examiner with appropriate training and expertise,
a reproductive history, and at least one properly performed (high
quality) semen analyses.
- A full evaluation by an urologist or other specialist in male repro-
duction should be carried out if the initial screening evaluation
demonstrates an abnormal PE, an abnormal male reproductive or
sexual history, or an abnormal semen analysis is found.
- Further evaluation of the male partner should also be considered in
couples with unexplained infertility and in couples in whom there is
a treated female factor and persistent infertility (Fig. 3, Table I).
There are signiﬁcant areas for future research. For example, what
constitutes the most appropriate minimal PE and does this provide sig-
niﬁcant additional information for male health in general, does perform-
ing a PE improve male engagement in diagnosis and treatment, what is
the cost-effectiveness of doing a PE on all men attending an infertility
clinic instead of doing a PE only after abnormal ﬁndings in semen ana-
lysis and/or an abnormal reproductive and sexual history, can a glo-
bally validated questionnaire/topic list for reproductive and sexual
history be used (encompassing low-income settings) to identify indivi-
duals at risk for male infertility, and Is the outcome better with earlier
diagnosis and is treatment less expensive with earlier diagnosis?
What is the clinical (ART/non ART) value
of traditional semen parameters?
Speciﬁcally, we posed two clinical questions. This ﬁrst question was
whether the predictive value of semen analysis for reproductive out-
come is better using a combination of several parameters compared
to a single semen analysis parameter, and the second was whether an
evaluation of a single ejaculate versus two ejaculates is sufﬁcient for
referral to infertility investigation and treatment.
A fundamental challenge in the analysis of the literature is the qual-
ity of the laboratory testing which is often performed using sub-
optimal methods (Keel, 2004; Björndahl et al., 2016). This is illu-
strated by data presented from three recent national quality control
programmes in Belgium Germany and Italy (Mallidis et al., 2012;
Filimberti et al., 2013; Punjabi et al., 2016) documenting that, in gen-
eral, a number of laboratories do not adhere to WHO methods for
semen analysis. Lack of adherence to recommended and appropri-
ately standardized methods signiﬁcantly undermines the potential
diagnostic value. Effective strategies to address this issue remain a
subject of signiﬁcant debate (e.g. Carrell and De Jonge, 2016).
The analysis of studies to address this PICO question was limited to
those published after 1 January 2000, based on two key assumptions.
First, there has been a very slow increase in compliance with WHO
recommendations for semen analysis. The fourth edition was published
in 1999 and few publications before that bear evidence of signiﬁcant
and clear compliance with the recommended techniques (see
Tomlinson et al., 1999). Second, evaluation of the prognostic value of
semen analysis is dependent on the quality of the clinical interventions
available. It is, therefore, likely that ‘historic’ data for ART success are
not relevant for treatments available in recent years as the ART techni-
ques have signiﬁcantly improved (Wade et al., 2015).
Another major challenge which has been recognized for over 70
years is the substantial overlap in the distribution of semen analysis
results in fertile men and those from men in infertile couples
(MacLeod, 1950; Guzick et al., 2001; Cooper et al., 2010). This
means that comparing a patient’s semen parameters to the distribu-
tion of results for fertile men is not in itself sufﬁcient to determine
whether or not the patient is fertile or infertile (Björndahl, 2011).
Additionally, semen analysis is only part of the investigation of the
man and a number of other attributes contribute to his fertility
potential.
With regard to the ﬁrst question namely, Is the predictive value of
semen analysis for reproductive outcome better using a combination
of several parameters compared to a single semen analysis parameter?
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Studies were regarded as eligible if they presented primary data on
predictive values [or odds ratios (OR)] concerning multiple or single
analysis parameters. Four studies provided data on multiple assess-
ments of parameters (Zinaman et al., 2000; Guzick et al., 2001;
Jedrzejczak et al., 2008; van der Steeg et al., 2011, total n = 5022)
and 10 studies focussed on single ejaculate parameters as predictors
of fertility. Studies identifying a single semen parameter with signiﬁ-
cant predictive power for fertility are relatively common but the dis-
criminatory power is very often low e.g. expressed as receiver
operating characteristic curve/area under the curve (ROC–AUC)
close to 0.500 or OR including 1.00 in the 95% CI. In contrast, stud-
ies that have investigated multiple parameters, which are more
reﬂective of testicular production/function and maturation, for
example Guzick et al. (2001) and Jedrzejczak et al. (2008), present
OR or predictive values, that are comparable to diagnostic laboratory
tools in other areas of modern clinical medicine (Boyd, 2010). As
such the conclusion of this analysis was that examination of multiple
parameters was more predictive.
In summary, we strongly recommend based on a high quality of
evidence that the assessment of a combination of several ejaculate
parameters is a better predictor of fertility success than a single par-
ameter (Table I).
The second fundamental question is commonly posed but rarely
answered: Is an evaluation of a single ejaculate versus two ejaculates
sufﬁcient for referral to infertility investigation and treatment? This
was considered important globally, due to the low level of male
engagement to address reproductive health issues in many settings.
As above, the analysis was limited to studies published after 1 January
2000 primarily due to the presumed advances in quality in laboratory
andrology. In this analysis, studies were only eligible if they provided
appropriate information to ascertain the reliability of the data
obtained from semen analysis, and they presented primary data con-
cerning the usefulness of repeat analyses [e.g. intraclass correlation
coefﬁcient (ICC), where an ICC close to 1.00 indicates high reliability
between a pair of assessments].
Only ﬁve studies (Francavilla et al., 2007; Stokes-Riner et al., 2007;
Mishail et al., 2009; Leushuis et al., 2010; Christman et al., 2013 total
n = 6482) provided information that could be used to support or
reject a recommendation concerning analysis of a single versus two
ejaculates (see Supplementary Data for a detailed analysis of the stud-
ies). Analysis that included measures such as the ICC demonstrates
the reliability of a single ejaculate for referral to infertility investigation
and treatment leading to the conclusion that examination of a single
ejaculate is sufﬁcient. This conclusion is consistent with ASRM and
EAU recommendations. For example, the ASRM (2015a) state ‘that
at a minimum, the initial screening…should include analysis of at least
one semen sample’ and the EAU state that ‘if the results of semen
analysis are normal according to WHO criteria, one test is sufﬁcient’
(Jungwirth et al., 2015). The question is whether there is a sub-group
of men being investigated for infertility that require a repeat semen
analysis. If so, which group would this be? It is most likely to be men
with ejaculate results in between very good and very poor, i.e. those
Laboratory: including, but not limited 
to;
1. Semen analysis
2. Hormonal assays, if necessary
3. Genec assays, if necessary
a. Karyotype (PICO 6)
b. YCMD (PICO 6)
c. CFTR analysis (PICO 6)
Man in an 
inferle couple History
Physical 
Examinaon Semen Analysis
End of Male 
Invesgaon
Referral to Male 
Inferlity Specialist
Any abnormality
History: including, but not limited to;
1. Medical illness and medicaons
2. Surgical intervenons in the past
3. Sexual ability/limitaon
4. Cryptorchidism, scrotal infecons
5. Testosterone/anabolic usage
6. Lifestyle factors (see PICO 4)
a. obesity
b. smoking
7. Supplement usage (see PICO 5)
a. vitamins
b. oral anoxidants
8. History of malignancy (see PICO 7)
Physical: including, but not limited to;
1. Overall body habitus
a. obesity
b. muscular development
c. virilisaon
2. Testes
a. locaon, size, consistency
3. Ductal structures (vas, epididymis)
a. presence/absence
b. normal/obstructed
4. Spermac cord
a. varicocele (PICO 8)
b. hydrocele
++
Figure 3 Flowchart summary of algorithm for diagnosis of male infertility. As detailed in section PICO 2 (Is it necessary for all infertile men to
undergo a thorough evaluation?) the ﬁrst line investigations should include Physical Examination, History and Semen Analysis. Abnormalities in these
lead to further investigations. YCMD, Y chromosome microdeletion; CFTR, CF transmembrane conductance regulator.
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in the ‘intermediate’ range (Guzick et al., 2001). Guzick et al. (2001)
presented a model where patients were divided into three categories:
poor, intermediate and good ejaculate results. Creating three groups
for men undergoing infertility investigation may seem somewhat hypothet-
ical. However, there is a considerable overlap in ejaculate analysis results
from fertile and infertile men and the intermediate range corresponds
largely to this mixed group. For men with results in the ‘intermediate’
group a repeat analysis could provide further information—conﬁrming
earlier results or pointing to a less or more severe problem. It is,
therefore, logical to use a ‘borderline zone’ between good and very
poor results (Guzick et al. 2001; Björndahl, 2011), and perhaps restrict
repeat analysis to this mixed group.
However, a recommendation that analysis of a single ejaculate is
sufﬁcient to determine the most appropriate investigation and treat-
ment pathway is a controversial strategy. In some cases, this appears
contrary to conventional clinical practice where a plethora of well-
documented variables are known to affect semen analysis thus poten-
tially reducing the clinical value of a single ejaculate. Additionally, ana-
lyses of only one ejaculate is contrary to previous standard WHO
recommendations. However, a primary reason for the variability in
semen parameters is the failure of some laboratories to adhere to
standard WHO recommendations (Mallidis et al., 2012) and failure to
control for key parameters e.g. abstinence, that increases the variability
of the test. Importantly, the majority of these can be mitigated by
adopting and adhering to appropriate practices and WHO procedures
(WHO, 2010). Notwithstanding this, adoption of a strategy of analysis
of a single ejaculate should be accompanied by a detailed cost-beneﬁt
analysis to examine if and at what stage additional semen assessment,
particularly in the borderline zone, is appropriate. It is also important
to emphasize that this recommendation applies only to referral for
infertility investigation and treatment, and is not relevant, for example,
if the aim of a study it to establish a ‘true’ value of sperm production
or sperm output rate, for example, where a single ejaculate is not sufﬁ-
cient (Amann and Chapman, 2009).
In summary, we strongly recommend that based on a high quality of evi-
dence that analysis of a single ejaculate is sufﬁcient to determine the most
appropriate investigation and treatment pathway although semen analysis
could be repeated if one or more abnormalities are found (Table I).
There are a number of signiﬁcant areas for future. First, for
example, there is a need for large multi-centre studies to examine
the predictive values in semen analysis to identify men likely to con-
tribute to spontaneous pregnancy, ART pregnancy, fertilization fail-
ure, pregnancy loss/miscarriage, time to pregnancy (TTP) and live
birth. Second, a fundamental problem with developing new therapies
or diagnostic tests for male infertility is the limited understanding of
the formation, maturation and physiological workings of the normal
and dysfunctional spermatozoon. There is an urgent requirement to
understand these cellular, molecular biochemical and genetic mechan-
ism(s) in order to formulate appropriate diagnostic assays and
rational therapy for the male.
What key male lifestyle factors impact
on fertility?
This is, and is likely to remain, a topical issue. The focus of the ana-
lysis was on obesity, smoking and heat exposure.
Does obesity inﬂuence semen parameters?
Obesity is a global health problem. It impacts not only cardiovascular
diseases but also on many other related health disorders. Obesity
may adversely affect male reproduction by endocrinologic, thermal,
genetic and sexual mechanisms (Reis & Dias, 2012). As such, obesity
must be considered as a potential causal factor in male infertility.
However, two key meta-analyses published in this area show con-
ﬂicting data (MacDonald et al., 2010; Sermondade et al., 2013) with
the latter concluding: ‘overweight and obesity were associated with
an increased prevalence of azoospermia and oligozoospermia’.
Additionally, there are a number of cross-sectional and longitudinal
studies (MacDonald et al., 2013; Eisenberg et al., 2014 and Andersen
et al., 2015) that reported some negative associations between
semen parameters and obesity. A cross-sectional study of New
Zealand males (2013) showed that morphology was the only param-
eter that correlated with BMI (MacDonald et al., 2013). A longitudinal
study of American males reported an increased OR for decreased
ejaculate volume and total sperm count associated with obesity
(Eisenberg et al., 2014). Furthermore, the OR for lower sperm con-
centration and total sperm count increased with waist circumference.
A cross-sectional study of Norwegian men found a signiﬁcant decline
in all standard semen quality markers with increasing BMI. BMI was
also negatively associated with hormones of reproduction (Andersen
et al., 2015). A cross-sectional study of 4400 men attending infertility
clinics in the USA reported a signiﬁcant negative relationship between
obesity and semen parameters (Bieniek et al., 2016). Moreover, the
incidence of azoospermia and oligozoospermia was more prevalent
in obese men. Data from the CHAPS-UK study found no evidence
for an effect of BMI on either motile concentration (Povey et al.,
2012) or sperm morphology (Pacey et al., 2014). The ASRM con-
cluded in their ‘Obesity and reproduction: a committee opinion
paper committee opinion’ paper in 2015 that ‘obesity in men may be
associated with impaired reproductive function’ (ASRM, 2015b).
Based on the number of papers able to be included in each meta-
analysis paper (n = 31 and 25 for MacDonald et al., 2010 and
Sermondade et al., 2013, respectively) and the contradictory results,
along with cross-sectional and longitudinal study outcomes, a reason-
able conclusion is that additional well-controlled, population-based
trials are necessary before stronger conclusions regarding the poten-
tial impact of obesity on semen parameters can be made. The meth-
ods used to assess obesity should also be standardized. Obesity
studies should include measurement of reproductive hormones, as
the only meta-analysis paper (MacDonald et al., 2010) that included
hormonal parameters concluded ‘There was strong negative relation-
ship for testosterone, SHBG and free testosterone with increased
BMI.’ In a recent cross-sectional study, (Andersen et al., 2015) the
correlation between the three hormones and obesity was afﬁrmed.
Studies on the impact of weight-loss nutritional interventions on
reproductive health are missing. Bariatric surgical intervention reports
exist, however the outcomes are mixed and access is often restricted
based on socio-economic status.
In summary, the evidence supports a detrimental effect of obesity on
many aspects of health, and evidence is conﬂicting about a potential
effect on reproductive function. Therefore, we strongly recommend,
based on a moderate quality of evidence, that males presenting for fer-
tility evaluation should be counseled about weight-loss strategies when
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the BMI and waist circumference data demonstrate obesity and espe-
cially morbid obesity (Table I).
Does exposure to heat adversely affect semen parameters and/or
male fertility?
Perhaps surprisingly, the quality of the evidence linking heat to human
male infertility is relatively poor. Data from animals, primarily by experi-
mental manipulation of the testis, strongly suggest an adverse effect of
heat on spermatogenesis and subsequent fertility (Durairajanayagam
et al., 2015). Additionally, it is well established that cryptorchidism is
associated with abnormal spermatogenesis attributable, at least in part,
to heat exposure of the testes to core body temperature (Hutson
et al., 2013).
A key question is: When the testes are in the scrotum, does
heat exposure adversely affect semen parameters and male fertil-
ity? Many studies link certain activities to increases in scrotal tem-
perature (for example use of saunas, hot baths), but do not follow
this up with information about the effect on semen parameters
(Durairajanayagam et al., 2015). Of the studies that do investigate the
effect of temperature on semen parameters, fewer still provide indi-
cators of fertility outcomes such as live birth rate or TTP. Only
Thonneau et al. (1997) assessed TTP, and this study alone, with a
small sample size, was insufﬁcient to draw robust conclusions about
the effect of heat exposure on fertility. The reported reduction in
semen parameters caused by heat is often small and it is unclear
what effect, if any, this would have on biological fertility. For example,
Hjollund et al. (2000) reported a lower average sperm concentration
in men with higher scrotal temperatures, but this was still in the nor-
mal range (above 15 × 106/ml, WHO, 2010). Additionally, some
studies did not measure scrotal temperature, attributing a difference
in semen parameters to an activity without providing evidence that
there was any rise in testicular temperature (e.g. a study of taxi dri-
vers Figà-Talamanca et al., 1996).
No RCTs were found and almost all of the data were collected
retrospectively. Previous studies often suffer from small sample size
(e.g. Garolla et al., 2013) and confounding factors such as lifestyle fac-
tors (e.g. Figà-Talamanca et al., 1996). Very few of the studies used
control groups which further complicates interpretation. No system-
atic reviews or meta-analyses have been performed, which is prob-
ably because of the signiﬁcant variation in study design. The available
studies use different ages of participants, different outcomes, subject-
ive deﬁnitions of heat exposure, and even different criteria for semen
analysis (Zorgniotti & Seaﬂon, 1988 and Cherry et al., 2014).
Some studies investigated the effect of occupational heat exposure
on male fertility, for example welders. The evidence that this activity
affects male fertility is low, and extreme heat exposures such as this
do not represent the normal heat exposures of the general popula-
tion (caused by wearing different types of underwear, sedentary pos-
ition etc.). Povey et al. (2012) and Pacey et al. (2014) concluded that
there was no signiﬁcant effect of lifestyle factors, including heat
exposure, on semen parameters, and others also failed to ﬁnd a sig-
niﬁcant effect, for example, Støy et al. (2004) and Eisenberg et al.
(2015), although Priskorn et al., (2016) did report a negative associ-
ation between watching television for 5 h/day and sperm concentra-
tion but there was no measurement of heat exposure.
Sufﬁce it to say that further work is required to elucidate the
effects of heat exposure on male fertility. Ideally, scrotal temperature,
semen parameters and a measure of fertility outcomes, such as live
births, would have to be measured in prospective cohort studies.
Studies must use comparable measures of semen analysis, methods
for measuring scrotal temperature and deﬁnitions of infertility in
order for comparisons to be made. This would allow a systematic
review or meta-analysis of the evidence to be carried out.
In summary, we strongly recommend, based on a very low quality
of evidence, that there is insufﬁcient evidence to conclude that
exposure to heat, be it occupational or as a result of clothing or
body position, affect semen quality and/or male fertility (Table I).
Does cigarette (tobacco) smoking adversely affect semen
parameters and/or male fertility?
Most of the published literature on cigarette (tobacco) smoking and
male fertility only looks at the effect of smoking on semen para-
meters. The quality of the recent evidence linking cigarette smoking
to decreased semen quality is moderate, as a systematic review and
meta-analysis of 46 cross-sectional studies (Li et al., 2011) found that
smoking was associated with reductions in all of the semen para-
meters. A further meta-analysis of the literature since 2010 analysing
20 studies with 5865 participants (Sharma et al., 2016) also con-
cluded a signiﬁcant negative effect of cigarette smoking on all semen
parameters. One prospective cohort study was identiﬁed which
examined the effect of smoking status on semen quality (Yang et al.,
2015). This study reported a signiﬁcant reduction in total sperm
count (P = 0.012) and concentration (P = 0.023) after multivariate
analysis. Several cross-sectional and case-control studies found differ-
ing effects of smoking on semen quality. For example, Jeng et al.
(2014) reported a decreased proportion of sperm with normal
morphology in those who smoked >10 cigarettes/day (P = 0.04),
whilst Povey et al. (2012) found no signiﬁcant effect of smoking on
motile sperm concentration and Pacey et al. (2014) found no signiﬁ-
cant on sperm morphology. Several studies reported an association
between smoking and changes in blood hormone levels. For example,
Jeng et al. (2014), Al-Matubsi et al. (2011) and Lotti et al. (2015) all
reported increased serum testosterone in smokers compared to
non-smokers.
The deﬁnitions of smoking status vary between studies, with some
studies failing to deﬁne which participants they classed as ‘smokers’
(Caserta et al., 2013) and some studies using cotinine levels to evalu-
ate smoking status rather than pack-years or number of cigarettes
smoked per day. Lotti et al. (2015) considered those that had
smoked for <1 year to be ‘never smokers’. The studies also varied
on how they dealt with ex-smokers—in some studies only those who
currently smoked were ‘smokers’ and in others, anyone who had
exceeded 1-pack-year at any time in their life were ‘moderate smo-
kers’ (Anifandis et al., 2014). In some cases, smoking status was
divided into light, moderate and heavy, and again, these deﬁnitions
were inconsistent. These inconsistencies made it challenging for
Li et al. (2011) to establish a dose-dependent trend of smoking and
reduced semen quality. Much of the current evidence comes from
men presenting to infertility clinics, and may not represent the effect
of smoking on semen quality and/or fertility in the general popula-
tion. Also, smoking status was generally self-reported. This could
introduce bias to the evidence based.
There are few studies that examine the effect of smoking on indi-
cators of fecundity, such as TTP. One retrospective cohort study,
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Mutsaerts et al., (2012) found that paternal smoking had no effect on
TTP. ASRM (2012a) concluded that there was insufﬁcient evidence of
the association between smoking and male infertility, despite the fact
that smoking has been shown in many studies to affect semen quality,
however, a review of this recommendation is due to be published in
the near future.
Systematic review and meta-analysis are required to investigate the
effect of smoking on blood hormone levels, and of measures of
fecundity, such as TTP. However, this evaluation would require a
greater number of well-designed, prospective cohort studies with
consistent deﬁnitions of smoking status. The participants could be
stratiﬁed into levels of smoking, which could be assessed by biochem-
ical methods to reduce self-reporting bias. The outcomes should
include measurement of semen parameters as well as measures of
fecundity and fertility, such as TTP and live birth rate.
In summary, we strongly recommend based on a moderate quality
of evidence that there is some evidence to suggest a negative effect
of cigarette (tobacco) smoking on semen quality/male fertility but
not all studies report this. However, as smoking has an adverse effect
on general health and wellbeing it is recommended that men trying
for a pregnancy should abstain from smoking (Table I).
As stated previously the effect of lifestyle (and environmental fac-
tors) affecting male infertility is likely to remain a rapidly developing
and topical issue. There are a large number of signiﬁcant areas for
future research. Primarily large-scale prospective multi-centre trials
encompassing a variety of geographical locations are required to exam-
ine the effects of lifestyle (e.g. obesity, heat exposure, smoking, recre-
ational and medical drug use, high-intensity sports) and environmental
factors (e.g. occupational exposures, endocrine disrupting chemicals
(EDCs)/toxins) on spermatogenesis, semen analysis, male fertility and
fertility outcomes, including the health of subsequent offspring.
Do supplementary oral antioxidants and
herbal therapies signiﬁcantly inﬂuence
fertility outcomes for infertile men?
There is a signiﬁcant body of data to support the concept that oxida-
tive stress plays a key role in sperm dysfunction and male infertility
(Aitken et al., 2014). Consequently, antioxidant treatment of the
infertile man may improve semen quality and/or fertility. However,
the key question is: Are there data to support this? To address this
question two approaches were used: use of a recent Cochrane
review (updated; Showell et al., 2014); and primary analysis including
analysis of the literature on herbal therapies.
The Cochrane review (Showell et al., 2014) examined the use of
antioxidants. Forty-eight published studies were included in the sys-
tematic review with 37 studies included in the meta-analysis. In sum-
mary, only 7/48 trials reported on clinical pregnancy rate, only four
of which went on to report live births. The authors recommended
that until live birth and clinical pregnancy rate are robustly reported
by all infertility trials, it is not possible to draw clear conclusions on
the use of antioxidants for infertile men. Additionally, they concluded
that the low-quality evidence from only four small RCTs suggested
that antioxidant supplementation in infertile males may improve live
birth rates. Data were lacking on other adverse effects. Importantly
they suggested that ‘further large well-designed randomized placebo-
controlled trials are needed to clarify these results’. Our primary
analysis of the literature came to a similar conclusion as the
Cochrane review (Showell et al., 2014) as there were very few add-
itional studies examined (e.g. Raigani et al., 2014).
Far fewer studies examined the use of herbal therapies (Y virilin,
Saffron, Addyzoa). Two-thirds of the studies showed some improve-
ment in semen parameters and one study reported a positive effect
on sperm membrane integrity (Omu et al. 1998). Two studies
showed improvements in sperm DNA integrity after herbal therapy
(Omu et al. 2008; Raigani et al. 2014). After the use of herbal therap-
ies only one of three (33.3%) studies reported a positive inﬂuence on
pregnancy rates. Adverse effects were reported in 16.6% of the stud-
ies and most of them were mild to moderate. However, it is worth
noting the study of Safarinejad et al. (2011) within which a large num-
ber of patients had adverse haematological reactions during treat-
ment with the compound Linn Crocus sativus (Saffron).
An inevitable conclusion was that the methodological quality of
most studies in the literature on antioxidants and herbal therapies to
treat male infertility is poor. Additionally, the heterogeneity of the
selected studies makes meta-analysis challenging. A further complica-
tion is that techniques to measure oxidative stress, antioxidant cap-
acity and/or DNA damage are not standardized between all the
trials. Moreover, there is often a lack of clear pre-selection of a sub-
group for testing e.g. conﬁrmed high-reactive oxygen species/DNA
damage, reduced antioxidant capacity. Taking these factors into
account, oral antioxidant therapy may improve seminal oxidative sta-
tus in infertile men either by decreasing oxidative stress or by increas-
ing the total antioxidant capacity but the evidence is of poor quality.
In some cases, positive relationships are manifested in improvements
in semen parameters, most often sperm motility. This may explain
the higher pregnancy rates after antioxidant therapy compared to pla-
cebo but further detailed studies are required. Studies evaluating the
supplementation with herbs constitute only a small part of the avail-
able literature. For these studies, the heterogeneity of the trials do
not allow a robust conclusion to be drawn. Sufﬁce it to say, there are
no high-quality data to support the use of a single antioxidant or a
speciﬁc combination of antioxidants. Further, it is not possible to rec-
ommend an effective treatment regimen.
In summary, we strongly recommend based on low-quality evi-
dence that there are insufﬁcient data to recommend the use of sup-
plemental antioxidant therapies for the treatment of men with
abnormal semen parameters and/or male infertility. Additionally, we
strongly recommend based on very low quality of evidence that there
are insufﬁcient data to recommend the use of herbal therapies for
the treatment of men with abnormal semen parameters and/or male
infertility (Table I).
There are signiﬁcant areas for future research; there is an absolute
and urgent requirement for large, well-designed placebo-controlled
randomized trials with primary outcomes of TTP and live births
(including health of these births) reported in well-characterized
groups to examine, for example, the effects of dietary supplementa-
tion, vitamins and herbal remedies.
What are the evidence-based criteria for
genetic screening of infertile men?
The determination of whether an infertile male beneﬁts from having a
genetic evaluation depends on the aetiology of the reproductive
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compromise and the severity. A detailed history and comprehensive
PE, coupled with adjunctive tests, such as a semen analysis, hormone
assays and on occasion testis biopsy, help clarify to which diagnostic
category the patient belongs and, as a helpful consequence, assists in
determining which genetic studies may be fruitful. For example, if a
male has a reproductive history consistent with a known cause of
resultant spermatogenic failure, such as chemotherapy, bilateral
mumps, orchitis with resultant atrophy or current use of anabolic ster-
oids, and is presently severely oligozoospermic or azoospermic, it can
be assumed that these are the proximate reasons for the reduced/
absent spermatogenesis and no genetic evaluation needs to be under-
taken. The focus of the recommendations was on Karyotype, Y micro
deletions and cystic ﬁbrosis (CF) mutation analysis.
Y-chromosomal microdeletions and karyotype in men with
spermatogenic dysfunction
No Cochrane reviews were identiﬁed. The primary evidence was
from studies by Rozen et al. (2012), and Krausz et al. (2014) and
practice statements from ASRM (2012b), AUA (2011) and EAU
(Jungwirth et al., 2015). Based upon the evidence, we recommended
that in men who have a history, PE and hormonal assays consistent
with severe oligozoospermia or non-obstructive azoospermia
(NOA), both a karyotype and Y-chromosomal microdeletion assay
should be offered.
Karyotype: Men with a sperm count <5 million/ml show a much
higher rate of autosomal abnormalities than fertile populations
(around 4%) while the highest frequency is found in NOA men
(mostly Klinefelter syndrome). Klinefelter syndrome [47,XXY includ-
ing variants (48,XXXY), and XX males (SRY+ and SRY−)] is the
most common of the sex chromosomal aneuploidies. Translocations
may be found in a relatively small percentage of men with severe oli-
gozoospermia and azoospermia (Yatsenko et al., 2010). The beneﬁts
of knowing if there is a chromosomal abnormality are in the planning
for therapy and in the future follow up of the patient. As such, karyo-
type analysis should be performed prior to either use of ejaculated
sperm in conjunction with ICSI, or prior to operative testis sperm
extraction (TESE). The a priori knowledge of a chromosomal trans-
location, depending upon its exact nature, may signiﬁcantly alter the
thought process and therapeutic strategy of an upcoming ICSI cycle
by employing PGS to allow the transfer of only balanced or normal
embryos while discarding those that are chromosomally unbalanced
(e.g. Dul et al., 2012).
In summary, we strongly recommend, based on a high quality of
evidence, that karyotype testing should be performed on all males
with severe oligozoospermia (<5 × 106/ml) or NOA prior to any
therapeutic procedure (Table I).
Y-chromosomal microdeletion assay: The molecular geography of the
Y chromosome is such that microdeletions (not recognizable by cyto-
genetic methods) may occur that partially or completely eliminate the
azoospermia factor (AZF)a or the AZFb/c region from the genome,
and, consequently, any important ‘spermatogenic necessary’ genes
that reside in those intervals. Frequency data compiled by Rozen
et al. (2012) show an overall incidence of Y microdeletions in the
AZFc region in 1/27 men, which varied depending on the Y haplo-
type. The importance of Y microdeletion testing in the severely oligo-
zoospermic or azoospermic male prior to any therapy (ICSI using
ejaculated sperm or TESE) is for prognosis and consideration of
PGD. For example, data show that when a complete AZFa, AZFb or
AZFb/c microdeletion is present (~1–2% incidence of each in the
NOA man) no spermatozoa will be found on TESE. When there is
no possibility that sperm will be present, it is unhelpful and hurtful for
the male to be operated upon and, in the latter circumstance, for the
female partner to have an ovarian stimulation unnecessarily. Men
with AZFc microdeletions can produce spermatozoa that are capable
of fertilization, embryo development and term pregnancy (Oates
et al., 2002). An AZFc microdeletion results in a quantitative reduc-
tion in spermatogenesis with maintenance of spermatozoa quality and
function. All males born will directly inherit the AZFc microdeletion.
In summary, we strongly recommend, based on a high quality of
evidence, that Y chromosome microdeletion (YCMD) testing should
be performed on all males with severe oligozoospermia (<5 × 106/ml)
or NOA prior to any therapeutic procedure (Table I).
CF-mutation analysis in men with Congenital Bilateral Absence
of the Vas Deferens or clinical CF
No Cochrane reviews were identiﬁed. The primary evidence was
from studies by Yu et al. (2012), Xu et al. (2014) and Lommatzsch
and Aris (2009), and practice statements from ASRM (2012b), AUA
(2011) and EAU (Jungwirth et al., 2015).
Men with clinical CF (pulmonary and pancreatic dysfunction) will also
have absence of the vasa and seminal vesicles bilaterally and will, conse-
quently, have a low volume, low pH, and an azoospermic ejaculate.
The incidence in males of northern European heritage is 1:2000. An
equal frequency of men with low volume, acidic pH, azoospermia will
have congenital bilateral absence of the vas deferens (CBAVD) with lit-
tle respiratory or pancreatic disease, the vast majority of whom will
possess mutations/pathogenic abnormalities in both maternal and
paternal CF alleles. Whether one presents with respiratory tree (includ-
ing sinuses) and/or pancreatic disease, simply absence of the vas defer-
ens or somewhere clinically between these phenotypic extremes
depends upon exactly which mutations/abnormalities in the alleles are
inherited. There are >1985 recognized mutations in the CF transmem-
brane conductance regulator (CFTR) gene (Cystic Fibrosis Mutation
Database: The Hospital for Sick Children, Genetics and Genomics
Biology. Toronto: 1989 [Accessed: August 2014]. Available at: http://
www.genet.sickkids.on.ca/cftr/app.) The CFTR gene has 27 exons span-
ning 250 kb of chromosome 7 (7q31) and encodes an mRNA of 6.5 kb
and the ﬁnal protein contains 1480 amino acids. Certain mutations,
such as c.1521_1523delCTT (legacy name: F508del), severely impair
either quantity or functional quality of the CFTR protein determined by
that allele. Other abnormalities, such as the 5 T polymorphism in intron
8 (5 T), only mildly impair quantity or functional quality of the CFTR
protein determined by that allele. It is the combination of the two that
correlates to the severity of disease expression. If a person is homozy-
gous for c.1521_1523delCTT, for example, s/he will have problematic
respiratory and pancreatic disease manifested and diagnosed in child-
hood. However, if a male has inherited the ‘5 T’ allele and
c.1521_1523delCTT on the opposite allele and is therefore a com-
pound heterozygote, pulmonary and pancreatic function may be clinic-
ally normal and CBAVD is the only recognizable phenotypic
consequence. Bilateral vasal absence, then, is the most sensitive indica-
tor of a biallelic CF gene abnormality as there is differential expressivity
and sensitivity to CFTR in different epithelial tissues. In addition, it has
been postulated that severity of phenotype may be modiﬁed by
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polymorphisms in unrelated genes such as TGFB1 (transforming growth
factor) and EDNRA (endothelin receptor type A) (Havasi et al., 2010).
In a recent meta-analysis by Yu et al. (2012) of CBAVD patients, 78%
had at least one mutation identiﬁed, 46% had two mutations identiﬁed
and 28% had only one mutation identiﬁed. The most common hetero-
zygous mutation pairing was F508del/5T (17% of CBAVD cases) and
F508del/R117H (c.350G > A; 4% of CBAVD cases). The poly-
thymidine tract in intron 8 has three alleles consisting of 5, 7 and 9 thy-
midines that are found in 5, 85, and 10%, respectively, of the general
population. In the presence of 5T, there is reduced splicing of Exon 9
and, as a consequence, reduced expression of full-length CFTR.
Because 5T acts as a ‘mutation’ when trans (on the opposite allele) to
a deﬁned CFTR mutation, e.g. F508del, the poly-T tract in intron 8 must
be deﬁned in cases of CBAVD. Poly-T tract analysis is often only a
reﬂex assay when R117H is detected (Chen and Prada, 2014).
However, many of the studies in the meta-analysis of Yu et al. (2012)
were conducted in the early years after discovery of the association of
CBAVD and CF mutations, when only a small cohort of mutations was
known and searched for (Anguiano et al., 1992). The more comprehen-
sive the assay, the more patients will have their second abnormality
identiﬁed. Although a CFTR mutation genetic basis underlying most
cases of CBAVD was a statistical certainty, this meta-analysis provides
well-deﬁned summary values which, in all likelihood, will be modiﬁed
upwards in future years as even more complete CFTR assessment is
accomplished for men with CBAVD.
The distribution of CFTR mutations and polymorphisms differs
depending upon the ethnic/geographical origin of the patient/popula-
tion being studied. As reviewed by Lommatzsch and Aris (2009),
F508del is the most common mutation leading to CF worldwide but
varies in its frequency based upon ethnicity/geographical location:
70–80% in CF patients from northern Europe, 50% in CF patients
from southern Europe, 48% in African Americans, 46% in US
Hispanics, 30% in Ashkenazi Jews, 18% of Tunisian CF patients and
rarely in Native Americans. Furthermore, in the Ashkenazi Jewish
population c.3846G > A (legacy name W1282X) is the most com-
mon mutation found (48% frequency). The meta-analysis by Xu et al.
(2014) which speciﬁcally looked at F508del, 5T, and M470V, supports
the above ﬁndings, concluding that there are signiﬁcant associations
between F508del and CBAVD (P < 0.001, OR = 22.20, 95% CI =
7.49–65.79), 5T and CBAVD (P < 0.001, OR = 8.35, 95% CI =
6.68–10.43).
In situations of CF or CBAVD, it is always necessary to screen the
female partner for CF gene abnormalities so as to have a proper
assessment of the risks of any offspring inheriting one of the two
paternal mutations and the maternal mutation and presenting with
clinical CF or, at the least, CBAVD if male. In addition, the beneﬁt of
testing the male with CBAVD helps provide information for his sib-
lings who have a 75% chance of harbouring at least one (or possibly
both) of the mutations inherited by the patient from his parents.
Finally, patients may have mild CF symptoms such as ‘sinusitis’ or
‘bronchitis’, not previously recognized to be CF-mutation related and
which, with a full understanding of their genetic basis, may be thera-
peutically managed in a different fashion. Not all CBAVD appear to
be caused by/associated with CFTR mutations and abnormalities, and
these cases may be secondary to a distinct genetic aetiology that
affects mesonephric duct development. The phenotypic end-product
may be CBAVD and unilateral renal agenesis, as described by
McCallum et al. (2001). Therefore, in cases of CBAVD where no
CFTR mutations are identiﬁed, renal ultrasonography is indicated.
In summary, we strongly recommend based on the high quality of
evidence that appropriate CFTR mutation analysis should be offered
to all males with CBAVD or CF (Table I).
There are signiﬁcant areas for future research in the genetic
screening of the infertile male. For example, what are the long-term
health outcomes of children born from infertile men, can cost-
effective tools for genetic screening in men (karyotype, Y micro dele-
tions and CF-mutation analysis) in low-income settings be developed,
and what is the genetic basis of unilateral absence of the vas asso-
ciated with unilateral renal agenesis?
How does a history of neoplasia and related
treatments in the male impact (his and his
partners) reproductive health and fertility
options?
In a number of aspects this was a very challenging question to
address. Although there were several reviews in the area, for
example Tournaye et al. (2014) and Samplaski and Nangia (2015),
and key recommendations from national societies, for example
American Society of Clinical Oncology (ASCO) (Loren et al., 2013),
the therapeutic agents and treatment regimens are continually evolv-
ing. Additionally, there were limited data on key aspects of the ques-
tion, such as advice on the contraception window post-treatment
and health of the offspring of both juvenile and adults cancer
survivors.
However, on a general level, there is consistency in the recom-
mendations of the major medical societies in Europe and USA: the
European Society for Medical Onclology (Peccatori et al., 2013) and
ASCO (Loren et al., 2013). For example, storage of semen samples is
the primary option to potentially preserve fertility of men (and boys
producing sperm in the ejaculate) who are undergoing chemo/radio-
therapy regimes (Loren et al., 2013; Peccatori et al., 2013). As such,
the overwhelming evidence suggests that all patients should be pro-
vided with information about the impact of their cancer treatment on
spermatogenesis and the option of sperm banking. Whether regi-
mens carry a high or lower likelihood of long-term fertilty impair-
ment, given the variability in individual response to treatment and the
potential for relapse, the evidence would recommend that sperm
cryopreservation should always be considered and services be avail-
able and affordable.
Counselling should also include the fact that there is little chance
of recovery from azoospermia after 10 years following radiotherapy
(Sandeman, 1966), total body irradiation (Rovó et al., 2006) or
chemotherapy (Meistrich et al., 1992, Heikens et al., 1996), however,
contraception should continue to be considered if paternity is not
desired. Actively attempting pregnancy during cancer treatment must
be avoided, however, if an accidental pregnancy would occur during
cancer treatment this should not automatically be considered an indi-
cation for elective termination. The pregnant couple should be
offered counselling and appropriate foetal diagnostic interventions,
for example, minimally an evaluation of the foetus through ultrasound
(De Santis et al., 2008).
Although the fertility of male cancer survivors is reduced, registry
data have identiﬁed subgroups dependent on cancer type, age at
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onset, treatment modality and dose, whose fertility is not different
from the general population (Tournaye et al., 2014). Pregnancy out-
comes, such as pre-term delivery, low-birth rate and miscarriages,
seem to be comparable to the general population but there are con-
ﬂicting data regarding the risk of malformations (Ståhl et al., 2011).
Generally, a co-ordinated approach between the healthcare profes-
sionals involved in cancer treatment and the reproductive medicine
specialists is highly recommended although regrettably not always
achieved.
In summary, we strongly recommend that based on moderate
quality of evidence that every male cancer patient should be provided
with information about the impact of his cancer treatment on sperm-
atogenesis and the option of sperm banking. Additionally, we strongly
recommend based on low quality of evidence that: patients should
be advised to use contraception if they do not wish to procreate
even after prolonged periods of azoospermia following radiotherapy,
as recovery is possible; male cancer patients should be informed that
pregnancy outcomes in partners are good but a slightly higher risk of
congenital anomalies in their offspring cannot be excluded (Table I).
There are signiﬁcant areas for future research. For example, there
are insufﬁcient data to advise men regarding the contraception win-
dow post-treatment and a lack of systematic data on the risk of birth
defects following accidental conception during treatment. It also has
to be determined if there are any effects in second generations of
cancer survivors following cancer treatment; there are no data
regarding the risk to partners or offspring from chemotherapeutic
agents in semen.
What is the impact of varicocele on male
fertility and does correction of varicocele
improve semen parameters and/or fertility?
For this question, and after discussion with this working group of
experts and with the leads of the WHO GDG, a recommendation
was made to use the Practice Committee of the ASRM; Society for
Male Reproduction and Urology (2014). Report on varicocele and
infertility: a committee opinion (evidence level IV). As the method-
ology used to construct this report was not equivalent to the WHO
GRADE assessment, the conclusions cannot be suggested as a rec-
ommendation but as an opinion based on a review of the literature.
As such these are suggested as Good Practice Points, namely:
- Treatment of a clinically palpable varicocele may be offered to the
male partner of an infertile couple when there is evidence of abnor-
mal semen parameters and minimal/no identiﬁed female factor,
including consideration of age and ovarian reserve.
- IVF with or without ICSI may be considered the primary treatment
option when such treatment is required to treat a female factor,
regardless of the presence of varicocele and abnormal semen
parameters.
- The treating physician’s experience and expertise, including evalu-
ation of both partners, together with the options available, should
determine the approach to varicocele treatment.
An analysis by Shridharani et al., (2016) presents a detailed assess-
ment of the EAU, ASRM and AUA recommendations on varicocele.
The differences in their recommendations and the complexities of
conducting a long-term prospective trial that would deﬁnitively
answer this question clearly indicate that signiﬁcant further research
is necessary to guide clinical management.
Challenges and future research
opportunities
It was perhaps an inevitable conclusion that, in conducting these ana-
lyses, gaps in the literature would be identiﬁed. It would be surprising
if this was not the case. However, what was surprising was the sub-
stantial nature of the gaps where effectively little or sometimes no
research had been performed. Of additional note was the sometimes
low quality of the available evidence. Such a combination makes for-
mulating informed evidence-based decisions for the diagnosis of the
male difﬁcult (see Table I for summary). However, conversely, a
number of issues were identiﬁed with clear and signiﬁcant opportun-
ities for the way forward.
Key themes in developing these
recommendations
Areas for research focus
We present key areas for research focus that demand investigation.
Overall one high priority area for research was to gain a better
understanding of the production, formation and workings of a human
spermatozoon. There is an urgent requirement to understand these
cellular, molecular biochemical and genetic mechanism(s) in order to
formulate appropriate diagnostic assays, develop rational therapy for
the male, and understand how external factors, such as the environ-
ment, negatively or positively inﬂuence these processes. Not surpris-
ingly, this is not unique to our discipline. For example, a new strategy
to understanding neurodegeneration with a primary focus on the
formation and function of the cell is now strongly advocated as abso-
lutely essential to accelerate progress for understanding neurodegen-
erative disorders (Kosik et al., 2016). Although research in
understanding the workings of the human spermatozoon has pro-
gressed signiﬁcantly over the last 10 years, there is still the need to
catch up and then keep pace with the knowledge base in other cellu-
lar systems. It is unlikely that a series of robust diagnostic tools for
sperm function can be developed without further detailed under-
standing of the working of the normal and dysfunctional cell.
Additionally, without this knowledge, the complementary develop-
ment of a drug(s) that a man can take or have added to his sperm-
atozoa in vitro to improve sperm function will continue to remain
elusive. Premature introduction of putative but unproven diagnostic
and/or therapeutic tools into clinical practice in ART can hinder
rather than advance progress in the ﬁeld for the long-term (Harper
et al., 2012, 2017; Spencer et al., 2016).
An additional high priority theme area for research was to examine
the long-term health outcomes of the children born from men with
compromised fertility (including those who may also have been trea-
ted with ART) whatever the nature of the compromising event(s)
(e.g. genetics, environmental, iatrogenic and/or occupational).
Moreover, this analysis needs to assess the effects in various geo-
graphical locations. In addition to the research themes which accom-
pany each question, we identiﬁed other areas that require addressing.
For example, what is the impact of age on male fertility? What are
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the underlying causes related to the male for IVF–ICSI treatment fail-
ure? Which gene (or epigenetic) defects in men can predict ART out-
comes? What are the most effective educational initiatives towards
improving understanding of male infertility? What are the attitudes of
men and women (in various geographical locations) towards the
investigation of male fertility? Certainly, in presenting this analysis, a
plethora of research questions has been generated.
Requirement to obtain robust data
A consistent theme was the focus on the quality of evidence available
to support any recommendations. The criteria used can be presented
in two, not mutually exclusive, formats: Traditionally, the quality of
evidence is represented by using a range of different levels. However,
it is clear that a considerable degree of the research related to the
diagnosis of male infertility does not easily ﬁt into these categories.
The evidence is sometimes observational and not easily amenable to
meta-analysis. With respect to the scientiﬁc and clinical evaluation of
diagnostic methods i.e. methods that measure characteristics of the
individuals, RCT are not usually appropriate. Primarily there is no
inclusion of a separate group to be used as a control i.e. a group not
obtaining the investigated treatment. In the evaluation of a diagnostic
method, the control of the diagnostic method can be obtained with
another independent method, or from the ﬁnal clinical outcome.
From this point of view, the highest level of evidence cannot easily be
obtained through a RCT.
Where data/evidence were available the quality of the evidence
was often judged to be sub-optimal. One issue was the robustness of
studies and thus general applicability. The robustness of the evidence
base in reproductive medicine has been discussed (Evers, 2013,
Barratt, 2016a, 2016b; Glujovsky et al., 2016) and is of course not
just a theme in reproductive medicine (Baker, 2016). Robust meth-
ods must be developed and subsequently utilized. One example
where we have perhaps made relatively little progress is the technical
challenges of semen analysis. However, with a greater appreciation of
the difﬁculties in this arena (Carrell and De Jonge, 2016) now is per-
haps the time for the WHO to produce a 6th version of the semen
assessment manual. The evidence based for the current (5th version)
manual is at least 10 years out of date and a lot has changed.
Nevertheless, there are areas of good practice: European Academy
of Andrology guidelines and recommendations for quality control of
the Y-chromosomal microdeletion assay (Krausz et al., 2014) are
commonly used. Robustness also applies to the veriﬁcation of key
recommendations from, for example, professional societies (see
Ventimiglia et al., 2016). In the future we need to heed the lessons of
the past and make sure the evidence base, including the use of robust
tools, is signiﬁcantly improved.
The theme of international studies
Male infertility is a global and signiﬁcant health problem. A consistent
theme is the requirement for national and international efforts with
large-scale, multi-centre studies encompassing different geographical
locations. Considerable regional variations in key indices of male
reproductive health have been reported (Skakkebaek et al., 2016)
but these are often on a relatively local scale. It is critical to under-
stand potential variations in sentinel markers of male reproductive
health, in other countries/regions as well as in low and middle
resource settings globally, in order to inform on further policy and
practice.
Context of resource setting
A key theme is the question of global implementation of diagnostic
tools and therapeutic procedures, and especially in low-resource set-
tings. Basic procedures do require resources and some recommenda-
tions although very simple procedures (e.g. sperm banking prior to
potentially sterilizing cancer therapy) may be feasible in most settings
but unfortunately they may not be in some areas without specialized
storage facilities.
Overall summary: the road
to a healthy future for male
infertility
There are signiﬁcant advances in male reproductive health from
developments on in vitro spermatogenesis to dissecting the workings
of the mature spermatozoon. However, progress in this arena is
comparatively slow. The robustness of the data is sometimes want-
ing, and thus the ability to provide the strongest evidence-based
guidelines has proven to be a challenge. We provided recommenda-
tions based upon the evidence available. However, when looking to
the future there is a need to understand why it has happened that
the data are limited and not forthcoming, in order to inform the dir-
ection of future initiatives and endeavours that could result in more
studies that yield robust evidence from men residing in high-, middle-
and low-income country settings.
What is the scale of the problem of male
infertility and its consequences?
It is fundamental to know the prevalence of a disease in order to pro-
vide resources, estimate impact, make effective health economic
arguments, present rational research questions and manage patients.
However, there is a paucity of clinical data on the scale of the repro-
ductive health problems and infertility in men on a global level, across
all health economies. The best estimates on infertility from demo-
graphic health studies use the heterosexual woman, as she self-
reports a problem with becoming pregnant, which further assumes a
diagnosis of female infertility (due to minimal if any reporting of clin-
ical diagnosis of the female), or possibly, an assumption of an infertile
relationship; and, coupled with an even larger paucity of male diagno-
sis and management of infertility in low- and middle-income coun-
tries, any male infertility prevalence values based upon demographic
health reports or from small private clinics are, at best, greatly extra-
polated and highly inaccurate (Mascarenhas et al., 2012). As a conse-
quence, there is limited information on fundamental key markers
such as the socio-economic impact that infertility and other diseases
or disorders may have on the individual and society as a whole.
Emphasizing the importance of the engagement of the male partner
in the assessment of the infertile couple and the education of the
public about male infertility should improve the care of the couple
and expand our knowledge of the scale of the problem.
Moreover, there is an urgent need to determine the potential con-
sequences of male infertility. This is a wide area of investigation which
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should extend beyond the conﬁnes of the couple and their immediate
relationships to investigate, for example, the relationship of infertility
with other diseases and what impact this has on the disease. There is
increasing evidence (albeit currently primarily in animals) of the
potential transmission to the next generation of damaging insults to
the male germ line by epigenetic mechanisms (Siklenka et al., 2015).
This may become especially relevant with the effect of signiﬁcant
potential changes in the external environments on the ﬁdelity of the
germ line, and also the likely future potential use of more immature
(Tanaka et al., 2015), and even in vitro generated, gametes.
Funding the science to match the scale
of the problem
The lack of data in key areas reﬂects the overall paucity of high qual-
ity long-term national and international funding streams to support
reproductive medicine, and male infertility in particular. Whilst this
has been discussed previously it remains a fundamental block to fur-
ther progress and a critical issue (Evers, 2013; Barratt, 2016a,
2016b). The WHO has not published evidence-based guidelines in
this area, and the previous infertility/fertility manual for management
of the infertile male based upon then current practice, was published
in 1992. This effectively means ~25 years without an update on best
practice and never any ofﬁcial guidelines for adoption and adaptation
at country level. This is an unacceptable situation as the lack of uni-
versal international guidelines does not help advance the ﬁeld of male
infertility or male reproductive health in general. However, it is antici-
pated that these new evidence-based guidelines for the male will act
as a platform for studies helping to raise the proﬁle of male repro-
ductive health.
Fundamentally, it is necessary to make more robust arguments to
national and international agencies to help drive the research agenda
and subsequently place reproductive medicine, with demonstrated
impact on couples and individuals, at the vanguard of the funding
landscape. The coupling of EDCs and male reproductive health may
provide an example. In this ﬁeld strong scientiﬁc, socio-economic
healthcare and political arguments have consistently been marshalled
to support research into what has been termed an ‘epidemic’ of male
reproductive health problems (Hauser et al., 2015; Skakkebaek et al.,
2016; Trasande et al., 2016). The burden of the disease (via EDC)
has been estimated and an impact assessment made (e.g. Olsson,
2014; Hauser et al., 2015). For example, it is estimated that the EDC
may contribute substantially to male reproductive disorders and dis-
ease equivalent to a staggering €15 billion cost in the European
Union (Hauser et al., 2015) although these ﬁgures are subject to con-
siderable debate (e.g. Olsson, 2014; Woodruff, 2015). This type of
analysis needs to be developed and continually ﬁne-tuned for male
reproductive health as a whole if additional support for the basic sci-
ence and clinical base of male infertility are to be realized. We also
need to realize that this support needs to encompass educating
future students (some of whom will be consumers and others leaders
in the ﬁeld) by stressing the importance of studying reproductive
health in the school/further education system (Finney and Brannigan,
2017). Developing and marshalling arguments to decision makers are
a complex and continuous challenge. Male reproductive health needs
ﬁrstly a series of hard-hitting documents providing an evidence based
for the importance and challenges in our discipline. However, this is
only the start of the process as delivery on these recommendations
requires a myriad of discussions with international agencies, politi-
cians and key decision makers. Evidence alone does not determine
action—as exampled by the challenges in implementing regional,
let alone global, policy to deal with the increasing CO2 in the atmos-
phere (Malakoff, 2017). We need to marshal a whole series of skills
to effect policy, and scientiﬁc evidence on its own is insufﬁcient for
major policy changes (see Cairney, 2012, 2017). Stating the obvious—
evidence-based guidelines require high-quality evidence, which will
only be achieved with appropriate funding that will result in obtain-
ing that data. Without robust data from all segments of society,
the status of male reproductive health will remain invisible and the
reproductive health needs of men will remain neglected into the
foreseeable future.
Supplementary data
Supplementary data are available at Human Reproduction Update
online.
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